{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:56:40Z","timestamp":1782266200766,"version":"3.54.5"},"reference-count":44,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Few clinical trials have evaluated long\u2010term treatment of nail psoriasis with biologics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Safety and efficacy of adalimumab [ADA; Humira AbbVie Inc, North Chicago, IL, USA)] long\u2010term treatment (52\u00a0weeks) was evaluated in a phase\u20103, randomized trial in patients with moderate\u2010to\u2010severe plaque psoriasis and concomitant moderate\u2010to\u2010severe fingernail psoriasis. Results from the first 26\u00a0weeks (Period A) have been reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients receiving 40\u00a0mg ADA every other week or placebo in Period A, continued with or switched to 40\u00a0mg ADA every\u2010other\u2010week treatment in the subsequent 26\u2010week open\u2010label extension (OLE) period. Main efficacy evaluations were \u226575% improvement in total\u2010fingernail modified Nail Psoriasis Severity Index (mNAPSI 75) and achievement of Physician's Global Assessment for Fingernail Psoriasis of clear or minimal disease (PGA\u2010F 0\/1) with a \u22652\u2010grade improvement from baseline, across the trial for patients who continued ADA from Period A through the OLE (Continuous\u2010ADA Population). Safety was evaluated during the OLE and for patients receiving ADA at any time during the study (All\u2010ADA Population).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 217 patients initially randomized in Period A, 188 (86.6%; 94 in each treatment group) entered the OLE after completion of or early escape from Period A. For the Continuous\u2010ADA Population (<jats:italic>N<\/jats:italic>\u00a0=\u00a0109), endpoint achievement rates improved from OLE entry (Week 26) to Week 52, including total\u2010fingernail mNAPSI 75 (47.4\u201354.5%); PGA\u2010F 0\/1 (51.1\u201355.6%) and total\u2010fingernail mNAPSI\u00a0=\u00a00 (6.6\u201317.9%). Serious adverse event and serious infection rates for the All\u2010ADA Population (<jats:italic>N<\/jats:italic>\u00a0=\u00a0203) were 6.9% and 3.4%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this population of psoriasis patients with concomitant, moderate\u2010to\u2010severe nail psoriasis, long\u2010term efficacy and improvement in signs and symptoms of nail disease were demonstrated after every\u2010other\u2010week ADA treatment, including incremental improvements in rate of total clearance of nail disease. No new safety risks were identified for patients receiving at least one ADA dose across 52\u00a0weeks.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.15793","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T09:38:42Z","timestamp":1563183522000},"page":"2168-2178","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Adalimumab for nail psoriasis: efficacy and safety over 52\u00a0weeks from a phase\u20103, randomized, placebo\u2010controlled trial"],"prefix":"10.1111","volume":"33","author":[{"given":"B.E.","family":"Elewski","sequence":"first","affiliation":[{"name":"School of Medicine University of Alabama at Birmingham Birmingham AL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.S.","family":"Baker","sequence":"additional","affiliation":[{"name":"Skin &amp; Cancer Foundation Inc and Probity Medical Research Carlton Vic. Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Crowley","sequence":"additional","affiliation":[{"name":"Bakersfield Dermatology Bakersfield CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Poulin","sequence":"additional","affiliation":[{"name":"Centre de Recherche Dermatologique du Qu\u00e9bec M\u00e9tropolitain Qu\u00e9bec City QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Okun","sequence":"additional","affiliation":[{"name":"Fort Healthcare Fort Atkinson WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Calimlim","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Geng","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Reyes Servin","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Rich","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University Hospital Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000246274"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09831.x"},{"key":"e_1_2_6_4_1","first-page":"1","article-title":"Nail psoriasis as a severity indicator: results from the PsoReal study","volume":"2","author":"Radtke MA","year":"2011","journal-title":"Patient Relat Outcome Meas"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00112.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-08810-5_1"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.10.021"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.07.073"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12054_suppl"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh198"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000182250"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03364.x"},{"issue":"1","key":"e_1_2_6_13_1","first-page":"283","article-title":"The burden of nail psoriasis: a real\u2010world analysis from the Corrona Psoriasis Registry","volume":"79","author":"Callis\u2010Duffin K","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.2983"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03426.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03211.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000317775"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.07.042"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01347.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12996"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14033"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.053"},{"key":"e_1_2_6_23_1","first-page":"AB232","article-title":"Secukinumab shows high and sustained efficacy in nail psoriasis: week 80 results from the TRANSFIGURE study","volume":"1","author":"Reich K","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_24_1","first-page":"S12","article-title":"Secukinumab in the treatment of palmoplantar, nail, scalp, and pustular psoriasis","volume":"9","author":"Armstrong AW","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.384"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12553"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.736960"},{"key":"e_1_2_6_28_1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1684\/ejd.2012.1863","article-title":"Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study","volume":"22","author":"Paul C","year":"2012","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.029"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.03.519"},{"key":"e_1_2_6_31_1","first-page":"123","article-title":"The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis","volume":"34","author":"Cassell SE","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140177"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12664"},{"key":"e_1_2_6_35_1","unstructured":"World Health Organization.Body Mass Index (BMI) classifications. Accessed atwww.who.int(last accessed: 20 August 2019)."},{"key":"e_1_2_6_36_1","article-title":"Effect of secukinumab on clinical activity and disease burden of nail psoriasis: 32\u2010week results from the randomized placebo\u2010controlled TRANSFIGURE trial","author":"Reich K","year":"2018","journal-title":"Br J Dermatol"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2009.00024"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03221.x"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102030-00005"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.10.026"},{"issue":"1","key":"e_1_2_6_41_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1610-0387.2010.07412.x","article-title":"Scalp psoriasis","volume":"9","author":"Wozel G","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09791.x"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201244"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.15793","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15793","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.15793","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15793","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T06:26:54Z","timestamp":1694240814000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.15793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,4]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1111\/jdv.15793"],"URL":"https:\/\/doi.org\/10.1111\/jdv.15793","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,4]]},"assertion":[{"value":"2019-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}